Sophie Tartas

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.3K citations · Full text

Rituximab-Dependent Cytotoxicity by Natural Killer Cells

Sébastien Dall’Ozzo, Sophie Tartas, Gilles Paintaud et al. · Cancer Research · 2004 · 415 citations

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs

Florence Ranchon, Gilles Salles, Hans-Martin Späth et al. · BMC Cancer · 2011 · 117 citations · Full text